In about an hour, the BioFire JI Panel simultaneously targets a broad grouping of 31 causative pathogens and 8 antimicrobial resistance markers commonly associated with joint infections.
*Investigational use only. Currently under FDA review; panel menu subject to change. Not available for sale.
The BioFire JI Panel tests for a comprehensive grouping of Gram-positive and Gram-negative bacteria, yeast, and antimicrobial resistance genes commonly associated with joint infections.
It takes just one syndromic test, one small sample of synovial fluid, and about an hour to get results on 39 clinically relevant targets.
SAMPLE TYPE:
0.2 mL of synovial fluid
PERFORMANCE:
Overall 90.6% Sensitivity and 99.8% Specificity1
PART NUMBER:
BioFire JI Panel 30 Pouch Kit: RFIT-ASY-0139
GRAM-POSITIVE BACTERIA:
GRAM-NEGATIVE BACTERIA:
YEAST:
ANTIMICROBIAL RESISTANCE GENES:
Carbapenemases
• IMP
• KPC
• NDM
• Oxa-48-like
• VIM
Methicillin Resistance
• mecA/C and MREJ
ESBL
• CTX-M
Vancomycin Resistance
• vanA/B
Conventional testing for joint infections is complex, often requiring multiple patient samples, various send-out tests, and days of waiting for results. The BioFire JI Panel is a rapid syndromic test that delivers comprehensive results in one easy-to-read report.
Using PCR technology, the BioFire JI Panel offers a rapid sample-to-answer turnaround without sacrificing performance.
The BioFire JI Panel identifies pathogens and antimicrobial resistance markers at the molecular level, encompassing the common causes of joint infections. It is not impacted by prior antibiotic use and targets difficult-to-grow anaerobes.
Compared to conventional methods, it can help facilitate increased diagnostic yield and improved polymicrobial detection.
References: